Description
ProductAvailABIlity:InStock(deliverywithin2-3businessdays,noextrachargefordrop-shipping).
Ordering:ToplaceanorderviacreditcardorPOuseAddtoCartbutton(creatinganaccountisnotrequired).
TransfectionReagentfor CHOCells(Chinesehamsterovarycells,CCL-61)
- Twocomponentformulationenhanceslipidmediatedtransfectionefficiency
- Optimizedeasy-to-usetransfectionprotocolprovidedfortransfectionofsiRNA,DNA,mRNA,andmicroRNA
- KitincludesTransfectionEnhancerreagentandrecommendedtransfectionprotocol
- Hightransfectionefficacyinthe presenceofserum
- ExpandyourRNAiapplicationwithareagentoptimizedfordeliveryofbothsiRNAandplasmid
- DownloadinvitroCHOtransfectionprotocol:[PDF]
- Download CHOCRISPR/Cas9transfectionprotocol:[PDF]
- DownloadPowerPointpresentationforCHOcellstransfectionkit:[PPT]
- DevelopedandmanufacturedbyAltogenBiosystems
TransfectionEfficiency:
Reagentexhibitsatleast90%transfectionefficiencyofsiRNAdelivery.TransfectionefficiencywasdeterminedbyqRT-PCR.
TransfectionProtocolandMSDS:
DownloadAltogenBiosystemsTransfectionProtocol:[PDF]
DownloadMSDS:[PDF]
CHO CellLine:
Productionofrecombinantproteintherapeuticsisconsideredoneofthemostinnovativebiotechnologicaladvancesandcanbehighlyeffectivefortreatmentofmanydiseasesandconditions,includingcancers,geneticandautoimmunedisorders,andinfectiousdiseases.Variousnon-humanmammaliancelllinesaregenerallyusedfortheproductionoftherapeuticproteins,withChinesehamsterovary(CHO)celllinebeingthemostimportantbecauseofitsabilitytoperformhuman-likeproteinfolding.TheChineseHamsterOvary(CHO)tissuecelllinewasfirstestablishedin1957usingChineseHamster(Cricetulusgriseus)ovarycellsandisoneofthemostwell-usedcelllinesforclinicalresearch,andforthesynthesisoftherapeuticproteins.Also,thismammaliancelllineishighlyutilizedintransfectionaswellasinlarge-scalerecombinantproteinproduction.CHOcellsexhibitanepithelial-likecellmorphologyandareextensivelyemployedinbiomedicalresearchandbiotechnologyR&Dapplications.AltogenBiosystemsoffersthelipid-mediatedCHOtransfectionreagentkitforChinesehamsterovarycellsthatyieldsnearly90%transfectionefficiency.
Data:
Figure1.GAPDmRNAlevelswerequantifiedusingreal-timeRT-PCRintheCHOcellstransfectedwithsiRNAstargetingGAPDornon-silencingsiRNA.Forty-eighthourspost-transfection,thecellswereharvestedandanalyzedbyreal-timeRT-PCRforGAPDHmRNAexpressionlevels.Datawerenormalizedagainstthe18SrRNAsignal.Controlsampleswereeithermock-transfectedoruntreated.Valuesarenormalizedtountreatedsample.Dataaremeans±SD(n=3).
Figure2.ProteinexpressionofGAPDHinCHOcells.DNAplasmidexpressingGAPDHorsiRNAtargetingGAPDHweretransfectedintoCHOcellsfollowingAltogenBiosystemstransfectionprotocol.At72hourspost-transfectionthecellswereanalyzedbyWesternBlotforproteinexpressionlevels(normalizedbytotalprotein,10µgoftotalproteinloadedpereachwell).Untreatedcellsusedasanegativecontrol.
Selected invivo transfectionproductcitations(ALTOGEN® INVIVO TransfectionKits usedinthefollowingpublications):
- Nature.2008454(7203):523-7.Innateimmunityinducedbycomposition-dependentRIG-I…Saitoetal[PDF]
- Am JPathology.2010177(4):1870-80.RoleofocularcomplementfactorHinamurinemodel…Lyzogubovetal[PDF]
- NatureBiotechnology.201129(4):341-5.DeliveryofsiRNAtothemousebrainby…Alvarez-Ervitietal [PDF]
- Gastroenterology.2011141(2) Differential typeIinterferon-mediatedautophagictrafficking…Desaietal[PDF]
- PLoSPathog.201410(10)ExosomesfromhepatitisCinfectedpatientstransmitHCV…Bukongetal[PDF]
CHOTransfectionKit
AltogenBiosystems:
AltogenBiosystemstransfectionandelectroporationproductsforlifesciencesandcancerresearch.Transfectionreagentsaredevelopedforindividualcancercelllineandtransfectionprotocolsareoptimizedformaximumdeliveryefficiency.Advancedformulationofreagentsandoptimizedtransfectionprotocolsprovideefficientintracellulardeliveryofproteins,DNA,mRNA,shRNA,siRNA,andothernegativelychargedbiomoleculesin vitroandinvivo.Readmore abouttransfectiontechnologyatAltogen’sTransfectionResource.
AltogenLabsResearchServices:
AltogenLabsprovidesGLP-compliantcontractresearchstudiesforpre-clinicalresearch,INDapplications,anddrugdevelopment.BIOLOGyCROservices include:Xenograftmodels(30+),developmentofstablecelllines,ELISAassaydevelopment,cell-basedandtissuetargetedRNAistudies,safetypharm/toxassays,andotherstudies(visitAltogenLabs.com).
VolumeOptions:
- 0.5ml(Catalog#2055)
- 1.5ml(Catalog#2066)
- 1.5mlCRISPR(Catalog#2128)
- 8.0ml(Catalog#7029)
